

# Delayed hemolytic transfusion reaction in children with sickle cell disease: first 5-year retrospective study in mainland France


Claire Falguière,<sup>1</sup> Slimane Allali,<sup>2</sup> Bassem Khazem,<sup>1</sup> Annie Kamdem,<sup>1</sup> Cécile Arnaud,<sup>1</sup> Marie Belloy,<sup>3</sup> Corinne Guitton,<sup>4</sup> Marie-Hélène Odièvre,<sup>5</sup> Sophie Pertuisel,<sup>6</sup> Cecile Dumesnil,<sup>7</sup> Cécile Guillaumat,<sup>8</sup> Nathalie Garrec,<sup>9</sup> Alexandra Gauthier,<sup>10</sup> Perrine Mahe,<sup>11</sup> Valerie Soussan-Banini,<sup>12</sup> Laure Le-Carrer,<sup>13</sup> Etienne Merlin,<sup>14</sup> Audrey David,<sup>15</sup> Beatrice Pellegrino,<sup>16</sup> Catherine Paillard,<sup>17</sup> Jean-Francois Brasme,<sup>18</sup> Marie Lagarde,<sup>19</sup> France Pirenne<sup>20,21</sup> and Corinne Pondarre<sup>1,21</sup>

<sup>1</sup>Pediatric Department, Sickle Cell Disease Referral Center, Creteil; <sup>2</sup>Pediatric Department, Sickle Cell Disease Referral Center, Necker Hospital, APHP, Paris; <sup>3</sup>Pediatric Department, Center for Sickle Cell Disease, Aulnay sous-bois; <sup>4</sup>Pediatric Department, Sickle Cell Disease Referral Center, APHP, Kremlin-Bicetre; <sup>5</sup>Pediatric Department, Center for Sickle Cell Disease, Trousseau Hospital, APHP, Sorbonne Universite, INSERM UMRS 1134, BIGR, Paris; <sup>6</sup>Department of Pediatric Hemato-oncology, University Hospital of Rennes, Rennes; <sup>7</sup>Department of Pediatric Hemato-oncology, Hopital Charles Nicolle, Rouen; <sup>8</sup>Pediatric Department, Center for Sickle Cell Disease, Corbeil-Essonnes; <sup>9</sup>Pediatric Department, Center for Sickle Cell Disease, Jossigny; <sup>10</sup>Department of Pediatric Hemato-oncology, Hospices Civils de Lyon, Lyon; <sup>11</sup>Pediatric Department, Sickle Cell Disease Referral Center, Montpellier; <sup>12</sup>Pediatric Department, Center for Sickle Cell Disease, Boulogne-Billancourt; <sup>13</sup>Pediatric Department, Center for Sickle Cell Disease, Orsay; <sup>14</sup>Pediatric Department, Center for Sickle Cell Disease, Clermont-Ferrand University Hospital, Clermont-Ferrand; <sup>15</sup>Department of Pediatric Hemato-oncology, University Hospital of Saint-etienne, Saint-etienne; <sup>16</sup>Pediatric Department, Center for Sickle Cell Disease, Poissy; <sup>17</sup>Department of Pediatric Hemato-oncology and Bone Marrow Transplantation Unit, Hopital de Hautepierre, Strasbourg; <sup>18</sup>Department of Pediatric Hemato-oncology, University Hospital of Angers, Angers; <sup>19</sup>Pediatric Department, Center for Sickle Cell Disease, Bordeaux; <sup>20</sup>Etablissement Francais du Sang, Creteil, and <sup>21</sup>Universite Paris Est Creteil INSERM U955, Creteil, France

Correspondence:

C. FALGUIÈRE - [claire.falguiere@chicreteil.fr](mailto:claire.falguiere@chicreteil.fr)

<https://doi.org/10.3324/haematol.2022.281050>



Supplemental figure 1. Subsequent transfusion management and outcomes

DHTR: Delayed Hemolytic Transfusion Reaction; RBC: Red Blood Cell

2 patients underwent transfusion in pre-transplant setting, 1 for the management of multi-organ failure, 1 for acute splenic sequestration, 5 before surgery, and 2 for stroke prevention.